Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Building A Better Biomarker: PD-L1 Expression Under Spotlight At ASCO

Executive Summary

With new data showing correlation to response, use of PD-L1 expression as a biomarker for PD-1/L1 inhibitors was a frequent topic at ASCO. Its limitations point to need for better markers to guide immunotherapy use.

You may also be interested in...



IO Biomarkers: Where Do We Stand In 2017?

Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.

Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients

Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.

Publisher’s Spotlight: Shortlist Revealed For The 2021 Citeline Awards

From a record more than 100 entries, the finalists have been selected for 12 awards, representing the best and brightest of biopharmaceutical research. 

Topics

Related Companies

UsernamePublicRestriction

Register

PS056912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel